Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Inventory (2016 - 2025)

Adma Biologics (ADMA) has disclosed Inventory for 14 consecutive years, with $206.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Inventory rose 21.28% year-over-year to $206.5 million, compared with a TTM value of $206.5 million through Dec 2025, up 21.28%, and an annual FY2025 reading of $206.5 million, up 21.28% over the prior year.
  • Inventory was $206.5 million for Q4 2025 at Adma Biologics, up from $196.7 million in the prior quarter.
  • Across five years, Inventory topped out at $206.5 million in Q4 2025 and bottomed at $94.1 million in Q1 2021.
  • Average Inventory over 5 years is $158.6 million, with a median of $163.6 million recorded in 2022.
  • The sharpest move saw Inventory skyrocketed 80.05% in 2021, then decreased 3.12% in 2025.
  • Year by year, Inventory stood at $124.7 million in 2021, then surged by 30.91% to $163.3 million in 2022, then increased by 5.9% to $172.9 million in 2023, then decreased by 1.54% to $170.2 million in 2024, then increased by 21.28% to $206.5 million in 2025.
  • Business Quant data shows Inventory for ADMA at $206.5 million in Q4 2025, $196.7 million in Q3 2025, and $191.5 million in Q2 2025.